Share

April 06, 2015; 84 (14 Supplement) April 23, 2015

Alemtuzumab Slows Brain Volume Loss Over 4 Years Despite Most Relapsing-Remitting Multiple Sclerosis Patients Not Receiving Treatment for 3 Years (P7.263)

Alasdair Coles, Douglas Arnold, Jeffrey Cohen, Edward Fox, Hans-Peter Hartung, Eva Havrdova, Krzysztof Selmaj, David Margolin, Linda Kasten, Michael Panzara, D Alastair S Compston
First published April 8, 2015,
Citation
Permissions

Make Comment

See Comments

Downloads
0

Share

Article Information

vol. 84 no. 14 Supplement P7.263
Published By: 
Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology
Print ISSN: 
0028-3878
Online ISSN: 
1526-632X
History: 
  • First Published April 8, 2015.
Copyright & Usage: 
Copyright © 2015 by AAN Enterprises, Inc.

Author Disclosures

    1. Alasdair Coles10,
    2. Douglas Arnold8,7,
    3. Jeffrey Cohen2,
    4. Edward Fox1,
    5. Hans-Peter Hartung5,
    6. Eva Havrdova3,
    7. Krzysztof Selmaj6,
    8. David Margolin4,
    9. Linda Kasten9,
    10. Michael Panzara4 and
    11. D Alastair S Compston10
  1. Alasdair Coles10,
  2. Douglas Arnold8,7,
  3. Jeffrey Cohen2,
  4. Edward Fox1,
  5. Hans-Peter Hartung5,
  6. Eva Havrdova3,
  7. Krzysztof Selmaj6,
  8. David Margolin4,
  9. Linda Kasten9,
  10. Michael Panzara4 and
  11. D Alastair S Compston10
  1. 1Central Texas Neurology Consultants Round Rock TX United States
  2. 2Cleveland Clinic Cleveland OH United States
  3. 3First Medical Faculty, Charles University in Prague Prague Czech Republic
  4. 4Genzyme, a Sanofi company Cambridge MA United States
  5. 5Heinrich-Heine University Düsseldorf Germany
  6. 6Medical University of Lodz Lodz Poland
  7. 7Montréal Neurological Institute, McGill University Montreal QC Canada
  8. 8NeuroRx Research Montreal QC Canada
  9. 9PROMETRIKA, LLC Cambridge MA United States
  10. 10University of Cambridge School of Clinical Medicine Cambridge United Kingdom

Article usage

Article usage: April 2015 to October 2023

AbstractFullPdfSource
Apr 201511300Highwire
May 20155900Highwire
Jun 20154900Highwire
Jul 20154300Highwire
Aug 20155500Highwire
Sep 20158600Highwire
Oct 20154200Highwire
Nov 20154700Highwire
Dec 20153800Highwire
Jan 20161700Highwire
Feb 20161600Highwire
Mar 20161100Highwire
Apr 20161700Highwire
May 20161000Highwire
Jun 2016900Highwire
Jul 20161500Highwire
Aug 2016500Highwire
Sep 20161200Highwire
Oct 2016900Highwire
Nov 20161100Highwire
Dec 20161400Highwire
Jan 2017400Highwire
Feb 2017300Highwire
Mar 2017200Highwire
Apr 2017600Highwire
May 20172700Highwire
Jun 20176800Highwire
Jul 20171300Highwire
Aug 20172500Highwire
Sep 20171200Highwire
Oct 2017200Highwire
Nov 20171200Highwire
Jan 2018100Highwire
Feb 2018600Highwire
Mar 2018200Highwire
Apr 2018100Highwire
May 2018200Highwire
Jun 2018200Highwire
Jul 2018100Highwire
Sep 2018200Highwire
Nov 2018500Highwire
Dec 2018200Highwire
Jan 2019100Highwire
Feb 2019300Highwire
Mar 2019500Highwire
Apr 2019100Highwire
Jul 2019400Highwire
Sep 2019100Highwire
Nov 2019100Highwire
Apr 2020100Highwire
Jun 2020200Highwire
Jul 2020300Highwire
Aug 2020100Highwire
Oct 2020100Highwire
Nov 2020400Highwire
Dec 2020400Highwire
Jan 2021200Highwire
Mar 2021200Highwire
Apr 2021300Highwire
Jun 2021300Highwire
Jul 2021600Highwire
Aug 2021600Highwire
Oct 2021200Highwire
Nov 2021100Highwire
Dec 2021300Highwire
Jan 2022100Highwire
Feb 2022500Highwire
Mar 2022400Highwire
Apr 2022300Highwire
May 2022300Highwire
Jun 2022100Highwire
Jul 2022100Highwire
Aug 2022300Highwire
Sep 2022200Highwire
Oct 2022100Highwire
Nov 2022200Highwire
Jan 2023200Highwire
Feb 2023500Highwire
Apr 2023200Highwire
May 2023400Highwire
Jun 2023500Highwire
Sep 2023100Highwire
Oct 2023100Highwire

Letters: Rapid online correspondence

No comments have been published for this article.
Comment

REQUIREMENTS

You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.

Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.

If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.

Submission specifications:

  • Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
  • Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
  • Submit only on articles published within 6 months of issue date.
  • Do not be redundant. Read any comments already posted on the article prior to submission.
  • Submitted comments are subject to editing and editor review prior to posting.

More guidelines and information on Disputes & Debates

Compose Comment

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
NOTE: The first author must also be the corresponding author of the comment.
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. [email protected]
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Publishing Agreement
NOTE: All authors, besides the first/corresponding author, must complete a separate Publishing Agreement Form and provide via email to the editorial office before comments can be posted.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

You May Also be Interested in

Back to top
Advertisement

Related Articles

  • No related articles found.

Alert Me